An adaptive, biomarker-directed platform study of durvalumab in combination with targeted therapies in advanced urothelial cancer
Thomas Powles(St Bartholomew's Hospital), Dónal Landers(Cancer Research UK Manchester Institute), Robert McEwen(AstraZeneca (United Kingdom)), Matthew D. Galsky(Icahn School of Medicine at Mount Sinai), Petros Grivas(Fred Hutch Cancer Center), Iwanka Kozarewa(AstraZeneca (United Kingdom)), Pablo Maroto(Hospital de Sant Pau), Frédéric Rolland(Institut de Cancérologie de l'Ouest), Alain Ravaud(Bordeaux Population Health), Florence Joly(Inserm), Srikala S. Sridhar(Princess Margaret Cancer Centre), Danielle Carroll(AstraZeneca (United Kingdom)), Robert J. Jones, Daniel P. Petrylak(Radboud University Nijmegen), Gwénaëlle Gravis(Institut Paoli-Calmettes), Natalie Cook(The Christie NHS Foundation Trust), Arjun Vasant Balar(NYU Langone Health), Jan Cosaert(AstraZeneca (United Kingdom)), Darren Hodgson(AstraZeneca (United Kingdom)), Florence Mercier(AstraZeneca (United Kingdom)), Simon Chowdhury(Guy's Hospital), Aude Fléchon(Centre Léon Bérard), Richard Mather(AstraZeneca (United Kingdom)), Joan Carles(Vall d'Hebron Hospital Universitari)
Cited by 115
Related Papers
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
|New England Journal of Medicine|2017|3.4k
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
|New England Journal of Medicine|2014|3k
Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
|New England Journal of Medicine|2012|2.8k